In this seventh installment, Michael Pishvaian, MD, PhD, along with Tanios Bekaii-Saab, MD, discuss considerations to keep in mind when selecting first-line treatment options such as FOLFIRINOX or NALIRIFOX for patients with pancreatic cancer.
In this sixth installment, Tanios Bekaii-Saab, MD, and Shubham Pant, MD, discuss the role cost plays in selecting cancer regimens.
In this fifth installment, Shubham Pant, MD, and Tanios Bekaii-Saab, MD, discuss the best practices for treating adverse events associated with treatments such as FOLFIRINOX or NALIRIFOX.
To sign up for our newsletter or print publications, please enter your contact information below.
